These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 17876041)

  • 41. Chemoprevention of breast cancer with selective oestrogen-receptor modulators.
    Jordan VC
    Nat Rev Cancer; 2007 Jan; 7(1):46-53. PubMed ID: 17186017
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Selective estrogen receptor modulator delivery of quinone warheads to DNA triggering apoptosis in breast cancer cells.
    Peng KW; Wang H; Qin Z; Wijewickrama GT; Lu M; Wang Z; Bolton JL; Thatcher GR
    ACS Chem Biol; 2009 Dec; 4(12):1039-49. PubMed ID: 19839584
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Searching for an ideal SERM: Mining tamoxifen structure-activity relationships.
    Price S; Bender SG; Yahn R; Till NA; Varady S; LaLonde RL
    Bioorg Med Chem Lett; 2021 Nov; 52():128383. PubMed ID: 34592434
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer.
    Howell SJ; Johnston SR; Howell A
    Best Pract Res Clin Endocrinol Metab; 2004 Mar; 18(1):47-66. PubMed ID: 14687597
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Estradiol and selective estrogen receptor modulators differentially regulate target genes with estrogen receptors alpha and beta.
    Tee MK; Rogatsky I; Tzagarakis-Foster C; Cvoro A; An J; Christy RJ; Yamamoto KR; Leitman DC
    Mol Biol Cell; 2004 Mar; 15(3):1262-72. PubMed ID: 14699072
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Raloxifene: A selective estrogen receptor modulator (SERM) with multiple target system effects.
    Muchmore DB
    Oncologist; 2000; 5(5):388-92. PubMed ID: 11040275
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Arzoxifene, a new selective estrogen receptor modulator for chemoprevention of experimental breast cancer.
    Suh N; Glasebrook AL; Palkowitz AD; Bryant HU; Burris LL; Starling JJ; Pearce HL; Williams C; Peer C; Wang Y; Sporn MB
    Cancer Res; 2001 Dec; 61(23):8412-5. PubMed ID: 11731420
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparing the effects of 17β-oestradiol and the selective oestrogen receptor modulators, raloxifene and tamoxifen, on prepulse inhibition in female rats.
    Gogos A; van den Buuse M
    Schizophr Res; 2015 Nov; 168(3):634-9. PubMed ID: 25979306
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Raloxifene blocks estradiol induction of the serotonin transporter and 5-hydroxytryptamine2A receptor in female rat brain.
    Sumner BE; Grant KE; Rosie R; Hegele-Hartung Ch; Fritzemeier KH; Fink G
    Neurosci Lett; 2007 Apr; 417(1):95-9. PubMed ID: 17398000
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Tamoxifen and raloxifene suppress the proliferation of estrogen receptor-negative cells through inhibition of glutamine uptake.
    Todorova VK; Kaufmann Y; Luo S; Klimberg VS
    Cancer Chemother Pharmacol; 2011 Feb; 67(2):285-91. PubMed ID: 20383709
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cytochrome P450 3A4-mediated bioactivation of raloxifene: irreversible enzyme inhibition and thiol adduct formation.
    Chen Q; Ngui JS; Doss GA; Wang RW; Cai X; DiNinno FP; Blizzard TA; Hammond ML; Stearns RA; Evans DC; Baillie TA; Tang W
    Chem Res Toxicol; 2002 Jul; 15(7):907-14. PubMed ID: 12119000
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Endocrine manipulation in advanced breast cancer: recent advances with SERM therapies.
    Johnston SR
    Clin Cancer Res; 2001 Dec; 7(12 Suppl):4376s-4387s; discussion 4411s-4412s. PubMed ID: 11916228
    [TBL] [Abstract][Full Text] [Related]  

  • 53. An NO donor approach to neuroprotective and procognitive estrogen therapy overcomes loss of NO synthase function and potentially thrombotic risk.
    VandeVrede L; Abdelhamid R; Qin Z; Choi J; Piyankarage S; Luo J; Larson J; Bennett BM; Thatcher GR
    PLoS One; 2013; 8(8):e70740. PubMed ID: 23976955
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Selective estrogen receptor modulators (SERMs): mechanisms of anticarcinogenesis and drug resistance.
    Lewis JS; Jordan VC
    Mutat Res; 2005 Dec; 591(1-2):247-63. PubMed ID: 16083919
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The combination of the rexinoid, LG100268, and a selective estrogen receptor modulator, either arzoxifene or acolbifene, synergizes in the prevention and treatment of mammary tumors in an estrogen receptor-negative model of breast cancer.
    Liby K; Rendi M; Suh N; Royce DB; Risingsong R; Williams CR; Lamph W; Labrie F; Krajewski S; Xu X; Kim H; Brown P; Sporn MB
    Clin Cancer Res; 2006 Oct; 12(19):5902-9. PubMed ID: 17020999
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Designing the ideal selective estrogen receptor modulator--an achievable goal?
    Taylor HS
    Menopause; 2009; 16(3):609-15. PubMed ID: 19182697
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Analysis of cross-resistance of the selective estrogen receptor modulators arzoxifene (LY353381) and LY117018 in tamoxifen-stimulated breast cancer xenografts.
    Schafer JM; Lee ES; Dardes RC; Bentrem D; O'Regan RM; De Los Reyes A; Jordan VC
    Clin Cancer Res; 2001 Aug; 7(8):2505-12. PubMed ID: 11489833
    [TBL] [Abstract][Full Text] [Related]  

  • 58. 2-Phenylspiroindenes: a novel class of selective estrogen receptor modulators (SERMs).
    Blizzard TA; Morgan JD; Mosley RT; Birzin ET; Frisch K; Rohrer SP; Hammond ML
    Bioorg Med Chem Lett; 2003 Feb; 13(3):479-83. PubMed ID: 12565955
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A pharmacological review of selective oestrogen receptor modulators.
    Goldstein SR; Siddhanti S; Ciaccia AV; Plouffe L
    Hum Reprod Update; 2000; 6(3):212-24. PubMed ID: 10874566
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Molecular mechanisms involved in the protective actions of Selective Estrogen Receptor Modulators in brain cells.
    Baez-Jurado E; Rincón-Benavides MA; Hidalgo-Lanussa O; Guio-Vega G; Ashraf GM; Sahebkar A; Echeverria V; Garcia-Segura LM; Barreto GE
    Front Neuroendocrinol; 2019 Jan; 52():44-64. PubMed ID: 30223003
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.